Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes

Bibliography

• Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines 8th edition. Chest 2008;133:234-56
   PubMed Web of Science ®Google Scholar
• Turpie AG. Oral direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-47
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ. Oral anticoagulants in development- Focus on thromboprophylaxis in patients undergoing orthopedic surgery. Drugs 2006;66(11):1411-29
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Voith B, Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, The effect of extreme age, and gender , on the pharmacology and tolerability of rivaroxaban - an oral direct Factor Xa inhibitor. Blood 2006;108: abstract 905
   Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effects of a single dose BAY39-7959 – an oral direct factor Xa inhibitor – in subjects with extreme body weight. Blood 2005;106: abstract 1872
   Web of Science ®Google Scholar
• Kubitza D, Becka M, Wensing G, Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor- after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80
   PubMed Web of Science ®Google Scholar
• Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010;64(7):956-67
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). European public assessment report: Xarelto. Available from: http://www.emea.europa.eu [Last accessed October 2010]
   Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet 2009;48:1-22
   PubMed Web of Science ®Google Scholar
• Turpie AG, Fisher WD, Bauer KA, BAY 59-7939: an oral direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose ranging study. J Thromb Haemost 2005;3:2479-86
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris L, Dahl OE, Oral direct Factor Xa inhibition with BAY59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-28
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris I, Dahl OE, A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-81
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind randomized controlled trial. Lancet 2008;372:31-9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-85
   PubMed Web of Science ®Google Scholar
• Turpie Ag, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 2009;373:1673-80
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JH, Prevention of venous thromboembolism: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:338-400
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Eriksson BI, Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Throm Haemost 2010;105 (3) [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gallus A, Goldhaber S, Treatment of proximal deep venous thrombosis with the oral, direct factor Xa inhibitor rivaroxaban (BAY59-7939)- the ODIXa DVT (oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep vein thrombosis) study. Circulation 2007;116(2):180-7
   PubMed Web of Science ®Google Scholar
• Buller HR, Lensing AW, Prins MH, A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112(6):2242-7
   PubMed Web of Science ®Google Scholar
• Einstein investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510
   PubMed Web of Science ®Google Scholar
• Rocket AF study investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-7
   PubMed Web of Science ®Google Scholar
• Califf RM. Stroke prevention using the oral direct factor xa inhibitor Rivaroxaban compared with warfarin in patients with non valvular atrial fibrillation (ROCKET AF) [abstract 21839]. American Heart Association's Scientific Sessions; 2010
   Google Scholar
• Rothberg MB, Celestin C, Fiore LD, Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-50
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, Rivaroxaban versus placebo in patients with acute coronary syndromes (Atlas ACS -TIMI 46): a randomised double blind, phase II trial. Lancet 2009;374:29-38
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Orwat MJ, Koch S, Discovery of 1-(4-methoxyphenyl)7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-556
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Xin B, Apixaban, an oral, direct and selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2007;6:820-9
   Web of Science ®Google Scholar
• Wang L, Zhang D, Raghavan N, In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010;38(3):448-58
   PubMed Web of Science ®Google Scholar
• Lassen MR, Davidson BL, Gallus A, The efficacy and safety of apixaban, an oral, direct, factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5:2368-75
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A. Apixaban or enoxaparin for the thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus AS, Apixaban versus enoxaparin for the thromboprophylaxis after knee replacement (ADVANCE -2): a randomized double blind trial. Lancet 2010;375:807-15
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, Randomised double-blind comparison of apixaban and enoxaparin for thromboprophylaxis after hip replacement: the ADVANCE-3 trial. Pathophysiology of Haemostasis and thrombosis 2009;37(Suppl 1): abstract OC356
   Google Scholar
• Buller H, Deichman D, Prins M. Efficacy and safety of the oral direct facto Xa inhibitor apixaban for the symptomatic deep vein thrombosis. The Botticelli DVT dose ranging study. J Thromb Haemost 2008;6:1313-18
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Flaker G, AVERROES: Apixaban versus acetylsalicylic acid (ASA) to prevent strokes. In: Meeting ESC, editor, Stockholm; 2010. p. abstract 3769
   Google Scholar
• Alexander JH, Becker RC, Bhatt DL, Apixaban, an oral, direct, selective factor xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-85
   PubMed Web of Science ®Google Scholar
• Ogata K, Mendell-Harary J, Tachibana M, Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-53
   PubMed Web of Science ®Google Scholar
• Raskob G, Cohen AT, Eriksson BI, Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010;104(3):642-9
   PubMed Web of Science ®Google Scholar
• Weitz JI, Connolly SJ, Patel I, Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104(3):633-41
   PubMed Web of Science ®Google Scholar
• Weitz JI, Cao C, Eriksson BI, A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost 2010;104(6):1150-7
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer K, Davidson BL, A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101(1):68-76
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Turpie AG, Lassen MR, Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)
   Google Scholar
• Sabatine MS, Antman EM, Widimsky P, Otamixaban for the treatment of patients with non-ST elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomized, double blind, active controlled, phase 2 trial. Lancet 2009;374(9692):787-95
   PubMed Web of Science ®Google Scholar
• Agnelli G, Haas S, Ginsberg JS, A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007;5(4):746-53
   PubMed Web of Science ®Google Scholar
• Bellamy L, Rosencher N, Eriksson B. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Prefer Adherence 2009;3:173-7
   PubMed Web of Science ®Google Scholar